May 25, 2023Open Access

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Veracyte, INSERM, Labex Immuno-Oncology, Transcan ERAnet European project, ARC, SIRIC, CARPEM, Ligue Contre le Cancer, ANR, QNRF, INCa France, Louis Jeantet Prize Foundation.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Ghiringhelli et al. (Thu,) studied this question.

synapsesocial.com/papers/69da44b1387cf706986867c9 https://doi.org/https://doi.org/10.1016/j.ebiom.2023.104633

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Classifying Cancers Based on T-cell Infiltration and PD-L12015 · 1,451 citations
2Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)2021 · 13 citations
3Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer2018 · 214 citations
4A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade2018 · 1,195 citations
5Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice2017 · 364 citations

Perguntar à IA

Bookmark

View Full Paper